Ciprofloxacin

References

• Bergan T, Thorsteinsson SB, Kolstad IM, et al. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol 1986: 5(2): 187–92
   PubMedGoogle Scholar
• LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988: 8(1): 3–33
   PubMed Web of Science ®Google Scholar
• Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988: 35(4): 373–447
   PubMed Web of Science ®Google Scholar
• Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986: 18(Suppl D): 21–9
   PubMed Web of Science ®Google Scholar
• Nix DE, DeVito JM. Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials. Clin Pharm 1987: 6(2): 105–17
   PubMedGoogle Scholar
• Sanders CC. Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev Infect Dis 1988: 10(3): 516–27
   PubMedGoogle Scholar
• Miller KG, Liu LF, Englund PT. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 1981: 256(17): 9334–9
   PubMed Web of Science ®Google Scholar
• Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 1984: 3(1): 339–43
   PubMedGoogle Scholar
• Kayser FH, Novak J. In vitro activity of ciprofloxacin against gram-positive bacteria: an overview. Am J Med 1987: 82(4A): 33–9
   PubMed Web of Science ®Google Scholar
• Bauernfeind A. Antimicrobial activity of ciprofloxacin. In: Neu HC, Weuta H, eds. Proceedings of 1st International Ciprofloxacin Workshop. New York: Elsevier Science Publishing (Excerpta Medica), 1986: 7–11
   Google Scholar
• Wolfson JS, Hooper DC. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med 1988: 108(2): 238–51
   PubMed Web of Science ®Google Scholar
• Fass RJ, Helsel VL, Barnishan J, et al. In vitro susceptibilities of four species of coagulase-negative staphylococci. Antimicrob Agents Chemother 1986: 30(4): 545–52
   PubMed Web of Science ®Google Scholar
• Sanders WE Jr. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis 1988: 10(3): 528–43
   PubMedGoogle Scholar
• Daikos GL, Kathpalia SB, Lolans VT, et al. Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis. Am J Med 1988: 84(4): 786–90
   PubMed Web of Science ®Google Scholar
• Drusano GL. Pharmacokinetics of the quinolone antimicrobial agents. In: Wolfson JS, Hooper DC, eds. Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology, 1989: 71–105
   Google Scholar
• Bergan T, Dalhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 1988: 16 (Suppl 1): S3–13
   PubMed Web of Science ®Google Scholar
• Zeiler HJ, Peterson U, Gau W. Antibacterial activity of the metabolites of ciprofloxacin identified in human urine. (Abstr) Proceedings of 24th Inter-science Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1984: 983
   Google Scholar
• Lebel M, Bergeron MG. Pharmacokinetics in the elderly: studies on ciprofloxacin. Am J Med 1987: 82(4A): 108–14
   PubMed Web of Science ®Google Scholar
• Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. (Letter) Eur J Clin Microbiol 1985: 4(3): 345
   PubMedGoogle Scholar
• Ledergerber B, Bettex JD, Joos B, et al. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 1985: 27(3): 350–2
   PubMed Web of Science ®Google Scholar
• Leor J, Matetzki S. Ofloxacin and warfarin. (Letter) Ann Intern Med 1988: 109(9): 761
   PubMed Web of Science ®Google Scholar
• Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988: 10(Suppl 1): S141–6
   PubMedGoogle Scholar
• Wijnands WJ, van Herwaarden CL, Vree TB. Enoxacin raises plasma theophylline concentrations. (Letter) Lancet 1984: 2(8394): 108–9
   PubMed Web of Science ®Google Scholar
• Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med 1987: 82(4A): 115–8
   PubMed Web of Science ®Google Scholar
• Barriere SL. New fluoroquinolones. Hosp Ther 1988: 23 (Jul): 18–33
   Google Scholar
• Arcieri G, August R, Becker N, et al. Clinical experience with ciprofloxacin in the USA. Eur J Clin Microbiol 1986: 5(2): 220–5
   PubMedGoogle Scholar
• Preheim LC, Cuevas TA, Roccaforte JS, et al. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. Am J Med 1987: 82(4A): 295–300
   PubMed Web of Science ®Google Scholar
• Fong IW, Linton W, Simbul M, et al. Treatment of nongonococcal urethritis with ciprofloxacin. Am J Med 1987: 82(4A): 311–6
   PubMed Web of Science ®Google Scholar
• Arcieri G, Griffith E, Gruenwaldt G, et al. Ciprofloxacin: an update on clinical experience. Am J Med 1987: 82(4A): 381–6
   PubMed Web of Science ®Google Scholar
• Fass RJ. Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections. Antimicrob Agents Chemother 1987: 31(2): 148–50
   PubMed Web of Science ®Google Scholar
• Guibert J, Destree D, Konopka C, et al. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Eur J Clin Microbiol 1986: 5(2): 247–8
   PubMedGoogle Scholar
• Feist H, Vettner N, Drlicek M, et al. Comparative study of ciprofloxacin and cefalexin in the treatment of patients with lower respiratory tract infections. In: Neu, Weuta, eds,10 pp 265–7
   Google Scholar
• Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. J Antimicrob Chemother 1986: 18(Suppl D): 133–8
   PubMed Web of Science ®Google Scholar
• Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. Am J Med 1987: 82(4A): 202–7
   PubMed Web of Science ®Google Scholar
• Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987: 82(4A): 180–4
   PubMed Web of Science ®Google Scholar
• Peterson PK, Stein D, Guay DR, et al. Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. Am J Mea 1988: 85(2): 164–71
   PubMed Web of Science ®Google Scholar
• Khan FA. Ciprofloxacin in the treatment of lower respiratory tract infection due to Streptococcus pneumoniae. Int Med 1989: 10(10): 33–8
   Google Scholar
• Thadepalli H, Bansal MB, Rao B, et al. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev Infect Dis 1988: 10(3): 505–15
   PubMedGoogle Scholar
• Lesse AJ, Freer C, Salata RA, et al. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987: 82(4A): 247–53
   PubMed Web of Science ®Google Scholar
• Slama TG, Misinski J, Sklar S. Oral ciprofloxacin therapy for osteomyelitis caused by aerobic gram-negative bacilli. Am J Med 1987: 82(4A): 259–61
   Web of Science ®Google Scholar
• Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987: 82(4A): 266–9
   PubMed Web of Science ®Google Scholar
• Diridl G, Pichler H, Wolf D. Treatment of chronic Salmonella carriers with ciprofloxacin. Eur J Clin Microbiol 1986: 5(2): 260–1
   PubMedGoogle Scholar
• Carver PL, Fekety R. The quinolones: expanded choices and individual differences. Consultant 1988: 28(7): 59–67
   Google Scholar